235 related articles for article (PubMed ID: 21510726)
1. Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.
Lasker GF; Maley JH; Pankey EA; Kadowitz PJ
Expert Rev Respir Med; 2011 Apr; 5(2):153-61. PubMed ID: 21510726
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
3. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat.
Casey DB; Badejo AM; Dhaliwal JS; Sikora JL; Fokin A; Golwala NH; Greco AJ; Murthy SN; Nossaman BD; Hyman AL; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H184-92. PubMed ID: 20435851
[TBL] [Abstract][Full Text] [Related]
4. New insights into the role of soluble guanylate cyclase in blood pressure regulation.
Buys E; Sips P
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):135-42. PubMed ID: 24419369
[TBL] [Abstract][Full Text] [Related]
5. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
6. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
7. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
Chester M; Tourneux P; Seedorf G; Grover TR; Gien J; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2009 Aug; 297(2):L318-25. PubMed ID: 19465519
[TBL] [Abstract][Full Text] [Related]
8. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
Andersen A; Nielsen JM; Holmboe S; Vildbrad MD; Nielsen-Kudsk JE
J Cardiovasc Pharmacol; 2013 Aug; 62(2):167-73. PubMed ID: 23575263
[TBL] [Abstract][Full Text] [Related]
9. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
10. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
Priviero FB; Webb RC
J Cardiovasc Pharmacol; 2010 Sep; 56(3):229-33. PubMed ID: 20571429
[TBL] [Abstract][Full Text] [Related]
11. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
12. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
[TBL] [Abstract][Full Text] [Related]
13. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
14. Sodium nitrite causes relaxation of the isolated rat aorta: By stimulating both endothelial NO synthase and activating soluble guanylyl cyclase in vascular smooth muscle.
Ling WC; Lau YS; Murugan DD; Vanhoutte PM; Mustafa MR
Vascul Pharmacol; 2015 Nov; 74():87-92. PubMed ID: 26044183
[TBL] [Abstract][Full Text] [Related]
15. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
[TBL] [Abstract][Full Text] [Related]
16. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds.
Hagan G; Pepke-Zaba J
Expert Rev Respir Med; 2011 Apr; 5(2):163-71. PubMed ID: 21510727
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pulmonary hypertension.
Hoeper MM; McLaughlin VV; Dalaan AM; Satoh T; Galiè N
Lancet Respir Med; 2016 Apr; 4(4):323-36. PubMed ID: 26975811
[TBL] [Abstract][Full Text] [Related]
19. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF
Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686
[TBL] [Abstract][Full Text] [Related]
20. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Vermeersch P; Buys E; Pokreisz P; Marsboom G; Ichinose F; Sips P; Pellens M; Gillijns H; Swinnen M; Graveline A; Collen D; Dewerchin M; Brouckaert P; Bloch KD; Janssens S
Circulation; 2007 Aug; 116(8):936-43. PubMed ID: 17679618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
